drugset / Trial / NCT01238029
Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
Phase 1
Terminated
12 enrolled
Sponsor GmbH
Arbeitsgemeinschaft fur Internistische Onkologie · collabArbeitskreis Klinische Studien · collabGlaxoSmithKline · collabiOMEDICO AG · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
Timeline
- Start
- 2010-10
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Vinorelbine | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 22.5 mg/m2 | Intravenous |